Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

168
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
168
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

222
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
222
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

208
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
208
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

160
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
160

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photoswitchable Silver(I) Complex with Anticancer and Antimicrobial Potential.

ACS omega·2026
Same author

Surface-Modified Superparamagnetic Iron Oxide Nanoparticles (SPIONs) in a New Perspective for Prostate Cancer Therapy.

Nanotechnology, science and applications·2026
Same author

Antiviral effect of poly(styrene 4-sulfonate) (PSSNa) on feline calicivirus oral infections in cats-field study.

The veterinary quarterly·2026
Same author

Beta-cyclodextrin decorated hyaluronic acid-coated SPIONs for improved delivery of temozolomide.

International journal of pharmaceutics·2025
Same author

Hyaluronic Acid-Coated SPIONs with Attached Folic Acid as Potential T2 MRI Contrasts for Anticancer Therapies.

ACS applied materials & interfaces·2025
Same author

Polyelectrolytes Are Effective Cryoprotectants for Extracellular Vesicles.

ACS applied materials & interfaces·2024

Related Experiment Video

Updated: May 4, 2026

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

486

Polymeric delivery systems for dexamethasone.

Justyna Urbańska1, Anna Karewicz1, Maria Nowakowska1

  • 1Faculty of Chemistry, Jagiellonian University, 30-060 Kraków, Ingardena 3, Poland.

Life Sciences
|December 31, 2013
PubMed
Summary
This summary is machine-generated.

Glucocorticoids like dexamethasone treat inflammation but have side effects. Polymeric carriers may improve dexamethasone delivery, enhancing its effectiveness and safety for treating immune system disorders.

Keywords:
CarrierDrugGlucocorticoids

More Related Videos

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.0K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

10.0K

Related Experiment Videos

Last Updated: May 4, 2026

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices
08:26

Dissolving Microneedle Array Patches Manufactured By Solvent Casting Technique and Essential Characterization of Microneedle-Based Biomedical Devices

Published on: January 30, 2026

486
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
07:32

Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles

Published on: August 28, 2015

11.0K
Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

10.0K

Area of Science:

  • Pharmacology
  • Materials Science
  • Immunology

Background:

  • Glucocorticoids (GCs) are vital for managing inflammatory and immune conditions such as allergies, asthma, autoimmune diseases, and sepsis.
  • Despite their broad use, GCs exhibit pleiotropic effects, leading to significant adverse events.
  • Dexamethasone (DEX), a commonly used GC, is noted for its hydrophobicity and low bioavailability, contributing to its side effects.

Purpose of the Study:

  • To review polymeric carrier systems as a potential strategy for improving dexamethasone (DEX) delivery.
  • To explore methods for enhancing the efficacy and safety of DEX through advanced drug delivery systems.

Main Methods:

  • Literature review of existing studies on glucocorticoid therapy.
  • Analysis of research on polymeric nanoparticles and other carrier systems for drug delivery.
  • Evaluation of DEX's physicochemical properties and their impact on bioavailability and side effects.

Main Results:

  • Polymeric carriers show potential for encapsulating and delivering hydrophobic drugs like DEX.
  • Controlled release mechanisms can mitigate DEX-related side effects by improving bioavailability.
  • Advanced delivery systems may enhance therapeutic outcomes in inflammatory and immune-related diseases.

Conclusions:

  • Polymeric carrier systems represent a promising approach to optimize dexamethasone therapy.
  • Effective delivery systems can potentially reduce the toxicity associated with GCs.
  • Further research into these systems could lead to improved treatments for a range of conditions.